OBJECTIVE: To study the significance of intra-tumoral cavitation in the @entity1 with advanced NSCLC treated by rh- @entity10120 plus NP chemotherapy. METHODS: Fifty-seven @entity1 with advanced NSCLC were randomly assigned to receive chemotherapy with rh- @entity10120 plus NP or NP alone. The numbers of activated circulating endothelial cells (aCECs) were measured by flow cytometry. Chest computed tomography was performed to evaluate the efficacy after 2 cycles of chemotherapy. RESULTS: Cavitation occurred in 5 of 29 @entity1 in the rh- @entity10120 plus NP group, but not in any case of the NP group. Of the 5 @entity1 , there were 2 males and 3 females, with pathological types of 3 @entity420 , 1 @entity1358 and 1 @entity189 . All of these 5 cases had a peripherally located @entity5 in the CT scan. There was only one cavity in each case and most of these were roundish. Four cavities were situated in the center of the @entity5 and another one was eccentric. There were 3 cavities with thin wall and 2 with thick wall. Their average diameter was 2.7 cm. No hemoptysis occurred in these 5 @entity1 . The blood-supply of the @entity5 showed by perfusion CT images was inhibited in 3 cases after treatment. The average number of aCECs decreased from 323.2/10(5) to 33.0/10(5) after treatment. CONCLUSION: Intratumoral cavitation is a peculiar imaging characteristics after anti-angiogenic therapy, which may be caused by inhibition of blood-supply to the @entity5 . CT perfusion imaging and measurement of activated circulating endothelial cells may be helpful to predict the efficacy of anti-angiogenic therapy combined with chemotherapy.

[Analysis of cavitation of advanced NSCLC treated by rh- XXXX combined with NP chemotherapy].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity189 :: ('MESH:D002277', 'Disease') :: ['sarcomatoid carcinoma'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['adenosquamous cell carcinoma'] @entity10120 :: ('80781', 'Gene') :: ['endostatin'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']
@entity10120 :: (80781,Gene) :: ['endostatin']
